Skip to main content
. 2022 Feb 10;11(4):920. doi: 10.3390/jcm11040920

Figure 2.

Figure 2

(A) Dose escalation regimen for adult patients administered every 2 weeks. Dose-escalation strategy for olipudase alfa after the Phase 1B study [31]. The aim of the dose-escalation process of olipudase alfa is gradual sphingomyelin debulking to prevent high ceramide release. BMI, body mass index. (B) Dose escalation regimen for pediatric patients administered every 2 weeks. Dose escalation regimen of olipudase alfa phase I/II ASCEND PEDS [27].